| Literature DB >> 30406035 |
Xiang Wang1,2, Yuanliang Yan1,2, Xi Chen1,2, Shuangshuang Zeng1,2, Long Qian1,2, Xinxin Ren3, Jie Wei1,2, Xue Yang1,2, Yangying Zhou4, Zhicheng Gong1,2, Zhijie Xu5.
Abstract
Marsdenia tenacissima (MT), a traditional Chinese herbal medicine, has long been used for thousands of years to treat asthma, tracheitis, rheumatism, etc. An increasing number of recent studies have focused on the antitumor effects of MT. The effects of MT on cancer are the result of various activated signaling pathways and inhibiting factors and the high expression levels of regulatory proteins. MT can inhibit different cancer types including non-small cell lung cancer (NSCLC), malignant tumors, hepatic carcinoma, and so on. This article mainly focuses on the activities and mechanisms of MT. In addition, the efficacy and toxicity of MT are also discussed. Further studies of MT are required for improved medicinal utilization.Entities:
Keywords: Marsdenia tenacissima; antitumor activities; efficacy; malignant tumor; signaling pathways; toxicity
Year: 2018 PMID: 30406035 PMCID: PMC6206208 DOI: 10.3389/fonc.2018.00473
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The substances associated with Marsdenia tenacissima. The main components of the Xiao-Ai-Ping (XAP) injection is Marsdenia tenacissima (MT).
The compounds isolated from herb medicine MT and their anti-tumor activities in vivo and in vitro.
| MTE | Compound | HCC827/ER cells | Lung cancer | Axl, c-Met | Reversing multidrug resistance | 0.5–500 mg/ml | ( | ||
| Orally administration | HCC827/ER xenograft nude mice | EGFR | 5 g/kg | ||||||
| Tenacigenin D | Monomer | H460/ H460- Vbl cells | K-Ras, P-gp | 10, 20 μM | ( | ||||
| MTE | Compound | Injection | H460 xenografts nude mice | PI3K/AKT/mTOR ERK1/2 | Inducing apoptosis | 5 g/kg | ( | ||
| Injection | H1975 xenografts nude mice | Inhibiting proliferation, inducing apoptosis | 5 g/kg | ( | |||||
| H460,H1975 cells | 0.5–500 μl/ml | ||||||||
| HCC827 cells | 8 mg/ml | ( | |||||||
| MTE | Compound | Jurkat cells | Hematological Malignancy | PI3K/AKT/mTOR | Inhibiting proliferation, inducing apoptosis | 0–640 μg/ml | ( | ||
| Intraperitoneal injection | A20 lymphoma cells | MMP-2, MMP-9 | Inhibiting growth, decreasing angiogenesis | 0–50 μl/ml | ( | ||||
| Crude ethanolic extract | CME | Compound | Intraperitoneal injection | K562 xenografts nude mice | Bax, caspase-9, caspase-3, | Inducing apoptosis | 20–320 μg/mL | ( | |
| K562 cells | Cyclin D1 | Promoting G0/G1 arrest | |||||||
| Tenacigeno side A, 11α-O-benz oyl-12β-O-acetyl tenacigenin B | TGTA, TGTB | Monomer | Raji lymphoma cells | BCL2,BCL-XL,BID | Inducing apoptosis | 1, 10, 50 μL/mL | ( | ||
| Intraperitoneal injection | lymphoma bearing NOD/SCID nude mice | 25 mg/kg | |||||||
| Tenacisso side C | TGTC | Monomer | K562 cells | Bcl-2,Bcl-xL, Bax,Bak, caspase-9, caspase-3 | Inducing apoptosis | 0–40 μM | ( | ||
| Injected subcutaneously | K562 bearing nude mice | cycline D1 | Promoting G0/G1 arrest | 8, 16 mg/kg | |||||
| MT | Compound | HepG2 cells | hepatic carcinoma | CYP2D6, CYP3A4 | 10 mg/ml | ( | |||
| HepG2 cells | VEGF-A | Decreasing angiogenesis | 0, 2.5, 5, 7.5 mg/ml | ( | |||||
| MTP | Compound | Intragastrically | H22 tumor-bearing mice | GSH-Px,SOD,CAT | Enhancing immune, inhibiting tumor growth | 50, 100, 200 mg/kg | ( | ||
| Five main C21 steroids | FR5 | Compound | HepG2,Bel7402 cells | Hippo, PI3K-PTEN-mTOR | Inhibiting proliferation, inducing apoptosis | 80, 160 g/ml | ( | ||
| Tenacissimo side A, 11α-O-benz oyl-12β-O-acetyl tenacigenin B | TGTA, TGTB | Monomer | HepG2/Dox Cells | P-gp | Reversing multidrug resistance | 20 μg/mL | ( | ||
| MT | Compound | KYSE150, Eca-109 cells | Esophageal cancer | MAPK | Inhibiting proliferation | 0–200 mg/ml | ( | ||
| MT | Compound | MG63 cells | Osteosarcoma | Fas | Sensibilization | 50 mg/mL | ( | ||
| Total aglycones of MT | ETA | Compound | Oral administration | KB-3-1 tumor bearing mice | Oral epidermoid carcinoma | P-gp | Sensibilization | 250 mg/kg | ( |
| Polyoxypregnanes | POPs | Compound | SW620/Ad300, MCF-7/VP, MCF-7/FLV1000 cells | Colon carcinoma, Breast cancer | P-gp, MRP1, BCRP | Reversing multidrug resistance | 0.4, 2, 10 μM | ( |
Figure 2The mechanisms and biological effects of Marsdenia tenacissima in cancer research.